HomeNVV1 • FRA
add
Novavax Inc
Previous close
€7.32
Day range
€7.24 - €7.27
Year range
€4.56 - €11.23
Market cap
1.36B USD
Avg Volume
4.83K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 239.24M | -42.42% |
Operating expense | 53.28M | -53.23% |
Net income | 106.51M | -34.41% |
Net profit margin | 44.52 | 13.92% |
Earnings per share | 0.62 | -37.37% |
EBITDA | 113.23M | -34.63% |
Effective tax rate | 0.88% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 612.30M | -41.66% |
Total assets | 1.34B | -26.51% |
Total liabilities | 1.30B | -42.28% |
Total equity | 37.62M | — |
Shares outstanding | 162.42M | — |
Price to book | 31.81 | — |
Return on assets | 20.09% | — |
Return on capital | 126.06% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 106.51M | -34.41% |
Cash from operations | -127.46M | -140.56% |
Cash from investing | 111.10M | 129.81% |
Cash from financing | -1.04M | -100.40% |
Net change in cash | -9.50M | -104.76% |
Free cash flow | -124.92M | -122.15% |
About
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Founded
1987
Headquarters
Website
Employees
952
